BG
CYTK icon

Bellevue Group’s Cytokinetics CYTK Stock Holding History

Bellevue Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
19,007
+10,166
+115% +$730K 0.03% 96
2026
Q1 		$583K Sell
8,841
-384
-4% -$24.4K 0.01% 107
2025
Q4 		$586K Buy
9,225
+7,125
+339% +$443K 0.01% 127
2025
Q3 		$115K Sell
2,100
-1,641
-44% -$67.6K ﹤0.01% 139
2025
Q2 		$124K Hold
3,741
– – ﹤0.01% 133
2025
Q1 		$150K Sell
3,741
-7,200
-66% -$331K ﹤0.01% 138
2024
Q4 		$515K Hold
10,941
– – 0.01% 126
2024
Q3 		$578K Sell
10,941
-5,718
-34% -$319K 0.01% 125
2024
Q2 		$903K Buy
16,659
+1,019
+7% +$61.5K 0.01% 122
2024
Q1 		$1.1M Sell
15,640
-3,260
-17% -$252K 0.02% 118
2023
Q4 		$1.58M Sell
18,900
-18,200
-49% -$659K 0.02% 113
2023
Q3 		$1.09M Hold
37,100
– – 0.02% 126
2023
Q2 		$1.21M Sell
37,100
-17,100
-32% -$633K 0.02% 125
2023
Q1 		$1.91M Hold
54,200
– – 0.03% 117
2022
Q4 		$2.48M Sell
54,200
-17,000
-24% -$731K 0.03% 122
2022
Q3 		$3.45M Buy
71,200
+4,800
+7% +$231K 0.05% 113
2022
Q2 		$2.61M Sell
66,400
-2,600
-4% -$105K 0.04% 122
2022
Q1 		$2.54M Buy
+69,000
New +$2.45M 0.03% 129

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Group's CYTK Position: Q2 2026 in Review

Bellevue Group increased its Cytokinetics (CYTK) stake by 115% in Q2 2026, buying an estimated $730K and bringing the position to 19,007 shares worth $1.62M. The position accounts for 0.03% of the portfolio, ranked #96.

Bellevue Group first reported a position in CYTK in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.45M in Q3 2022. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Bellevue Group held 19,007 shares of Cytokinetics worth $1.62M as of Q2 2026.
  • Bellevue Group bought 10,166 Cytokinetics shares in Q2 2026, an estimated $730K.
  • Cytokinetics made up 0.03% of Bellevue Group's portfolio in Q2 2026, its #96 holding.
  • Bellevue Group first reported a position in Cytokinetics in Q1 2022 and has held it in 18 quarters since.
  • Bellevue Group's Cytokinetics position peaked at $3.45M in Q3 2022.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.